NOVARTIS

11 Apr 2024

Novartis
Basel, Switzerland
CH-4056

Reference: EudraCT 2021-001256-34 Novartis Protocol ID CAIN457X12301.

A randomized,parallel-group,double-blind,placebo-controlled,multicenter phase III study to investigate the efficacy and safety of secukinumab (Cosentyx) 300 mg administered subcutaneously in patient with active peripheral spondyloarthritis (pSpA).

Trial 2021-001256-34 was cancelled with no patient enrollment and as such, no results will be reported.